Director/PDMR Shareholding
1 August 2022 17:00 BST
Revised stock exchange announcement due to a formatting issue with the original announcement published at 1505 today, 1 August 2022. There have been no changes to the underlying information within the release.
Transaction by Person Discharging Managerial Responsibilities
AstraZeneca PLC (the Company) announced that on 29 July 2022 awards of AstraZeneca American Depositary Shares (ADSs) vested to Dr Aradhana Sarin, Executive Director and Chief Financial Officer. Each ADS represents one half of an Ordinary Share of $0.25 in the Company.
In accordance with the Agreement and Plan of Merger between the Company and Alexion Pharmaceuticals, Inc. (Alexion), Dr Sarin's in-flight share awards granted by Alexion were converted to awards over AstraZeneca ADSs under the AstraZeneca Global Restricted Stock Plan at the time of closing of the Alexion acquisition. The awards that vested on 29 July 2022 replaced in-flight Alexion awards originally granted to Dr Sarin between February 2019 and February 2021 under the Alexion 2017 Incentive Plan.
Following the withholding of shares to satisfy certain tax obligations arising on vesting, 67,523 ADSs vested.
For tax purposes, the fair market value of an ADS at vest of the awards was US$66.72, being the closing price on the last trading day preceding the vesting.
Further details are set out in the attached notification, made in accordance with the requirements of the EU Market Abuse Regulation (as it forms part of UK law pursuant to the European Union (Withdrawal) Act 2018.
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
| a) | Name | Aradhana Sarin | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Chief Financial Officer | ||||
| b) | Initial notification/Amendment | Initial notification | ||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | AstraZeneca PLC | ||||
| b) | LEI | PY6ZZQWO2IZFZC3IOL08 | ||||
| 4i | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Description of the financial instrument, type of instrumentIdentification code | AstraZeneca PLC American Depositary SharesCUSIP: 046353108 | ||||
| b) | Nature of the transaction | Acquisition of AstraZeneca PLC American Depository Shares pursuant to a vesting under the Global Restricted Stock Plan | ||||
| c) | Price(s) and volume(s) |
|
||||
| d) | Aggregated information- Aggregated volume- Price | Not applicable - single transaction | ||||
| e) | Date of the transaction | 29 July 2022 | ||||
| f) | Place of the transaction | Outside a trading venue | ||||
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.